Alpharma — Investor Day (December 2007)
125 slides from Alpharma's investor day presentation, Dec 18, 2007
Slide 1: Company Strategy and Pharmaceuticals Update
Company Strategy and Pharmaceuticals Update December 18, 2007 Four Seasons Hotel 57 East 57th Street New York, NY 10022
Slide 2: Welcome
Welcome Jack Howarth Vice President Investor Relations
Slide 3: Forward Looking Statement
Forward Looking Statement Statements made in this presentation include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those relating to future financial expectations, involve certain risks and uncertainties that coul
Slide 4: Webcast Information and Presentation Assumptions
Webcast Information and Presentation Assumptions This presentation is available in a listen only mode via the internet at http://www.streetevents.com, or http://www.alpharma.com until January 2, 2008. These materials are meant for use only in connection with the oral presentation being made by the c
Slide 5: Agenda
PRESENTERS TOPIC Agenda President &CEO Dean Mitchell Wrap Up Question & Answer Question and Answer President & CEO Dean Mitchell Strategic Progress Sr. Vice President Clinical Research & Medical Affairs Dr. Joseph Stauffer ALO-01 Phase III Clinical Results Sr. Vice President Clinical Research & Medi
Slide 6: Strategic Progress
Strategic Progress Dean Mitchell President and CEO December 18, 2007 Investor Meeting
Slide 7: What I Plan to Cover
What I Plan to Cover What we committed to last year Where we are in 2007 Where we are going in 2008 – 2012 December 18, 2007 Investor Meeting
Slide 8: Overall Strategic Direction
Overall Strategic Direction Create a high value specialty pharmaceutical business Three strong businesses with varying opportunities to achieve further growth and profitability organically and through business development activities Innovation funded from cash flows and financing Build capabilities
Slide 9: 2007 Execution of the Strategy
2007 Execution of the Strategy Pharmaceuticals: Invest to create a high value specialty pharma business Abuse-deterrent platform – positive Phase III results New product pipeline: FLECTOR ® patch, Ketoprofen in Transfersome ® gel, Tris Significant strengthening of talent and core capabilities; sales
Slide 10: 2007 Milestones Scorecard
Seven new product indications Two Chinese acquisitions Enterprise Delivering performance vs. guidance Enhanced capital structure Built capabilities 2007 Milestones -- Scorecard Launch 7 new products Leverage AD Technology to other molecules Execute Phase III clinical Program Building Credibility Thr
Slide 11: Building a Top-Tier Organization in 2007
Building a Top-Tier Organization in 2007 Increased leadership talent Additional Pharmaceutical experience on the Board – Ladell, U’Pritchard Business continuity – Campbell, Carlsson, Warner, Wrenn Key staff additions – Aigner, Spellman, Watts Infrastructure for a growing Pharmaceuticals business Sig
Slide 12: Where we are going in 2008 – 2012
Where we are going in 2008 – 2012 Continue to defend the core business Continue to execute on forward integration strategy Expand portfolio of products…seek opportunities, leverage relationships Continue organic growth programs: geographies, new indications and products Attack near-term input cost c
Slide 13: Total Company: Five Year Revenue Target
Total Company: Five Year Revenue Target Revenue $ in millions 2006 Pharmaceuticals API AHD 2011 1,000 1,500 What We Committed to Last Year December 18, 2007 Investor Meeting
Slide 14: Total Company: Updated Five Year Revenue Target
Total Company: Updated Five Year Revenue Target 2006 Pharmaceuticals API AHD 2011 1,000 1,500 Revenue $ in millions December 18, 2007 Investor Meeting
Slide 15: Total Company: 2007 – 2012 Five Year Revenue Target
Total Company: 2007 – 2012 Five Year Revenue Target Revenue $ in millions Transforming the Company Profile Targeting $1B in Revenues in 2009 2007 Pharmaceuticals API AHD 2012 500H 1,000 1,500 2,000 December 18, 2007 Investor Meeting
Slide 16: Strategic Opportunities In Pharmaceuticals
Strategic Opportunities In Pharmaceuticals Pain market has unmet needs NSAIDs Long- acting opioid abuse Significant market potential for products that address these needs Compelling clinical data on pipeline products Aggressive launch plans for FLECTOR ® Patch December 18, 2007 Investor Meeting
Slide 17: Pharmaceuticals Business Update
Pharmaceuticals Business Update Ronald Warner, PhD President Pharmaceuticals
Slide 18: What We Will Talk About
What We Will Talk About . . . KADIAN ® key metrics Current pipeline Market opportunities Topical NSAIDS Abuse Deterrence December 18, 2007 Investor Meeting
Slide 19: KADIAN Revenue Trends
$185 - $195 $160 - $165 KADIAN ® Revenue Trends $62 $102 $138 KADIAN ® Revenues Projected to Triple Over 5 Years December 18, 2007 Investor Meeting $0 $50 $100 $150 $200 2004 2005 2006 2007 Est. 2008 Guidance
Slide 20: KADIAN and AVINZA TRx Trends
KADIAN(r) and AVINZA(r) TRx Trends 2005-01 2005-02 2005-03 2005-04 2005-05 2005-06 2005-07 2005-08 2005-09 2005-10 2005-11 2005-12 2006-01 2006-02 2006-03 2006-04 2006-05 2006-06 2006-07 2006-08 2006-09 2006-10 2006-11 2006-12 2007-01 2007-02 2007-03 2007-04 2007-05 2007-06 2007-07 2007-08 2007-09 2
Slide 21: What We Will Talk About
What We Will Talk About . . . KADIAN ® key metrics Current pipeline Market opportunities Topical NSAIDs Abuse Deterrence December 18, 2007 Investor Meeting
Slide 22: Total Pain Market is Over $20B and Growing
Total Pain Market is Over $20B and Growing Source: Wolters Kluwer Health, Source ® PHAST Prescription Monthly, MAT 5/2007 Note: The pain market excludes most OTC analgesics and DMARDs. Large Market with Opportunity to Switch Generics to New Brands December 18, 2007 Investor Meeting Short-Acting Opio
Slide 23: Alpharma Will Have a Presence in Over 50% of the Pain Market
Alpharma Will Have a Presence in Over 50% of the Total Pain Market Source: Wolters Kluwer Health, Source ® PHAST Prescription Monthly, MAT 5/2007 Note: The pain market excludes most OTC analgesics and DMARDs. December 18, 2007 Investor Meeting Short-Acting Opioids $7.4B Long-Acting Opioids $3.3B Lid
Slide 24: Pain Treatment Paradigm: Alpharma Portfolio
Mild Acute Chronic Pain Treatment Paradigm FLECTOR(r) Patch Ketoprofen in Transfersome(r) gel Moderate Severe KADIAN(r) ALO-02 ALO-01 ALO-04 ALO-3a ALO-3b Abuse Deterrence Combination Pharmacologic Physical Packaging No A.D.T. Alpharma Portfolio
Slide 25: December 2006 Product Pipeline
December 2006 Product Pipeline Approved Phase 1 Target Launch Date Phase 3 Phase 2 TBD ALO-02 2009 ALO-01 Marketed KADIAN ® Capsules Beginnings of a Pipeline December 18, 2007 Investor Meeting
Slide 26: Strong Pharmaceutical Product Pipeline
Strong Pharmaceutical Product Pipeline 2011 Ketoprofen in Transfersome ® gel 2010 ALO-03b 2012 ALO-04 Approved Phase 1 Target Launch Date Phase 3 Phase 2 Q1 2009 Tirosint ® Softgel 2010 ALO-03a 2011 ALO-02 Q1 2009 ALO-01 Jan. 2008 FLECTOR ® Patch Marketed KADIAN ® Capsules Eight Potential Product La
Slide 27: KADIAN NT ALO-01 Announcing
KADIAN NT ALO-01 Announcing….
Slide 28: December 18, 2007 Investor Meeting
December 18, 2007 Investor Meeting
Slide 29: EMBEDA
EMBEDA TM
Slide 30: December 18, 2007 Investor Meeting
December 18, 2007 Investor Meeting
Slide 31: What We Will Talk About
What We Will Talk About . . . KADIAN(r) key metrics Current pipeline Market opportunities Topical NSAIDs Abuse Deterrence
Slide 32: Acute Pain
Acute Pain Acute pain states can be brief, lasting moments or hours, or they can be persistent, lasting weeks or as long as 6 months until the disease or injury heals 1,2 42% of adults in the United States experience pain daily and 89% monthly 3 99 million office visits for acute pain occurred in 20
Slide 33: US NSAID/COX-2 Market Is Large and Shifting
TRx TRx (millions) $ (billions) NSAID/COX-2 Market Prescriptions and Dollars NSAID/COX-2 Market is Large with Growth Shifting to NSAIDs US NSAID/COX-2 Market Is Large and Shifting Source: Wolters Kluwer Source ® Pharmaceutical Audit Suite PHAST Prescription Monthly December 18, 2007 Investor Meeting
Slide 34: NSAID/Cox-2/Lidocaine patch Marketplace
NSAID/Cox-2/Lidocaine patch Marketplace Product TRx Share Source: Wolters Kluwer Health, Source ® PHAST Prescription Monthly, MAT 08/07 Few Promoted Brands December 18, 2007 Investor Meeting ibuprofen 30% naproxen 15% diclofenac 6% meloxicam 9% All other NSAIDs 23% celecoxib 13% lidocaine patch 4%
Slide 35: Clinical Concerns With Oral NSAIDs / Cox-2s
1. Wilcox CM, et al. Clin Gastroenterol Hepatol . 2006;4:1082-1089. 2. Chou R, et al. Ann Intern Med . 2007;147:478-491. 3. Singh G, et al. Ann Rheum Dis 2007;66 (Suppl):509 Clinical Concerns With Oral NSAIDs / Cox-2s FLECTOR ® Patch has NSAID class labeling Nonspecific NSAIDs: upper and lower GI co
Slide 36: Conclusions: Topical NSAIDs
Conclusions: Topical NSAIDs Market for FLECTOR ® Patch is large At a time when physicians and patients concerns about NSAID/COX-2 safety are considerable, FLECTOR ® Patch could fulfill some of the unmet need for a novel pain therapy Relatively few products promoted in this space Physicians initial r
Slide 37: What We Will Talk About
What We Will Talk About . . . KADIAN(r) key metrics Current pipeline Market opportunities Topical NSAIDs Abuse Deterrence
Slide 38: The Long Acting Opioid Abuse Deterrent Opportunity
The Long Acting Opioid Abuse Deterrent Opportunity Abuse goes beyond the patient Physicians are concerned about abuse Physicians believe abuse-deterrent formulations are needed Physicians estimate significant market potential Physicians underestimate their role in abuse deterrence Opioid abuse is a
Slide 39: The Hidden Faces of Opioid Abuse
The Hidden Faces of Opioid Abuse Over 70% of Abusers Say Friends and Relatives are the Primary Source of Illicit Pain Relievers 1 1 Results From the 2006 National Survey on Drug Use and Health. December 18, 2007 Investor Meeting
Slide 40: The Abuse Deterrence Concern
The Abuse Deterrence Concern Not Concerned Somewhat Concerned Extremely Concerned 96% of Surveyed MD's Are Concerned About Abuse Source: Alpharma Primary Market Research
Slide 41: Abuse-Deterrent Opioid Products Will Fulfill a Significant Unmet Need
Abuse-Deterrent Opioid Products Will Fulfill a Significant Unmet Need Source: Alpharma Primary Market Research Importance of Having Abuse-Deterrent Opioid Formulation 79% of Surveyed MD’s Believe Having Abuse-deterrent Opioids are Very Important Not important Extremely Important December 18, 2007 In
Slide 42: The Abuse Deterrent Paradox
The Abuse Deterrent Paradox MD’s Are Concerned About Abuse, But Underestimate Their Role in The Problem Figures based on Alpharma Primary Market Research. * Long-acting opioids 79% of surveyed MD’s believe having abuse-deterrent opioids are very important 96% of surveyed MD’s are concerned about abu
Slide 43: Alpharma in a Lead Position in Abuse Deterrence
Sources: FDA, Clinicaltrials.gov, Alpharma data on file Alpharma in a Lead Position in Abuse Deterrence ALO-03b ALO-03a NDA Phase III Phase II Phase 1 Others ? ALO-04 ALO-02 Oxy-Nal (Elite) Remoxy (King) Targeting Q1 08 EMBEDA ™ Focus on Long Acting Opioid Development is Abuse Deterrence December 18
Slide 44: Abuse Deterrent: Conclusions
Abuse Deterrent: Conclusions Abuse is a significant issue in pain treatment MD’s are concerned about abuse, but need to be educated on the pathways of misuse, abuse and diversion Products with abuse deterrent features will represent a significant portion of the pain market and most of its promotiona
Slide 45: Summary
Summary Solid KADIAN ® performance Significant pipeline growth Both FLECTOR ® Patch and EMBEDA ™ on track to compete in markets of significant size Strong Pipeline in the Specialty Pain Space December 18, 2007 Investor Meeting
Slide 46: The Medical Need for Topical NSAIDs
The Medical Need for Topical NSAIDs Arthur L. Weaver, MD, MS, FACP, MACR Clinical Professor of Medicine Department of Medicine—Section of Rheumatology University of Nebraska Medical Center Omaha, Nebraska
Slide 47: Overview of Oral NSAID Therapeutic Class
Overview of Oral NSAID Therapeutic Class Current State of Therapy for Pain & Inflammation
Slide 48: Total NSAID Use Increasing
1.79 3.69 4.6 4.88 5.36 5.34 1.77 0 1 2 3 4 5 6 1999 2000 2001 2002 2003 2004 2005 NS NSAIDs COX-2 inhibitors Total NSAID Use Increasing IMS Health, IMS National Sales Perspectives TM , 2/2006 Among people ³ 65 years,70% used ³ 1 dose/week, 34% used ³ 7doses/week 1.79 1.44 1.24 1.1 1.08 1.28 1.94
Slide 49: Traditional Oral NSAID Limitations: GI Toxicity
Endoscopic injury in regular users 50%: mucosal erosions on upper endoscopy 15%-30%: gastroduodenal ulcers (45% at 6 mo) 70%: NSAID lower GI injury 23%: large lower GI erosions/ulcers Clinical upper GI Events: 2.7%-4.5% /yr Complications 1.0%-1.5% /yr Clinical lower GI events: 0.19%-0.89% /yr Intest
Slide 50: Risk Factors: Oral NSAID-Associated Ulcer Complications
2.2 5.6 6.1 6.4 7 9 13.5 0 15 Steroids Age >70 years Past uncomplicated ulcer Anticoagulant High-dose NSAIDs Multiple NSAIDs Past complicated ulcer Increased Risk (Odds Ratio) 5 10 Risk greatest within first month of use Gabriel SE, et al. Ann Intern Med. 1991;115:787-96. Garcia-Rodriguez LA, et al.
Slide 51: Strategies to Minimize Oral NSAID-Gastropathy
Identify individuals with risk factors for adverse events Stop NSAID Use non-NSAID analgesic Decrease NSAID dose Use lower-risk NSAID COX-2 selective inhibitor Prescribe medical co-therapy Proton pump inhibitor Prostaglandin analog: misoprostol In patients with very high risk, one protective strateg
Slide 52: Risk Of GI Bleed With NSAIDs or Coxib
Aspirin alone 3.2 Combination 15.4 Aspirin alone 2.8 Combination 15.8 1,034 cases; 2,068 controls Risk Of GI Bleed With NSAIDs or Coxib Drug Adjusted Relative Risk NSAID alone 4.7 COX-2 alone 1.3 Lanas A, García-Rodriguez LA. Gastroenterology . 2003;124:(Suppl 1):A93.
Slide 53: CV Risk With Celecoxib
Non-ASA users (n = 1421) 1.1% 2.6% # deaths/total pts 5/466 25/955 ASA users (n = 614) 0.9% 3.5% # deaths/total pts 2/213 14/401 Deaths from CV causes in APC Trial CV Risk With Celecoxib Placebo Celecoxib Solomon SD, et al. N Engl J Med. 2005;352:1071-80.
Slide 54: Balance GI & CV Risk
Complicated GI events with COX-2 than NSAIDs Serious CV events occurred at ~ equal rates For COX-2, in complicated upper GI events numerically greater than any CV events For every 1,000 patients treated for 1 yr with a COX-2 vs NSAID: 8 fewer upper GI complications 1 more fatal or nonfatal heart att
Slide 55: Addressing Unmet Needs
NSAIDs & COX-1 sparing agents proven efficacy Treat edema & hypertension aggressively Acetaminophen efficacy/safety? (CV, GI, BP) COX-1 sparing agents & NSAIDs may CV risk with prolonged use, high dosage, & in patients with CV risk Assess both CV & GI risk before initiating Larger trials, longer dur
Slide 56: Addressing Unmet Patient Needs
Topical NSAIDs Applied directly at site of pain Compared with transdermal applied away from painful site Available in EU & Asia >20 yrs Compounding Many in development 2 approved: FLECTOR ® patch: acute sprains, strains contusions Diclofenac gel: pain of osteoarthritis Addressing Unmet Patient Needs
Slide 57: FLECTOR Patch Clinical Data
Joseph W. Stauffer, DO Chief Medical Officer Sr. Vice President Clinical Research & Medical Affairs Adjunct Assistant Professor Johns Hopkins University Hospital Department of Anesthesiology & Critical Care Medicine Division of Pain Medicine FLECTOR ® Patch Clinical Data
Slide 58: Overview
Overview Regulatory and Worldwide Safety Status Pharmacokinetic Data Efficacy Data Safety Data
Slide 59: Regulatory Status
Regulatory Status The FLECTOR ® Patch (diclofenac epolamine topical patch) was approved by the FDA in 2007 for the indication of: Topical treatment of acute pain due to minor strains, sprains, and contusions First approved in Switzerland in 1993. Subsequently approved in 39 countries (15 in Western
Slide 60: Worldwide Safety Experience
Worldwide Safety Experience Over 6 million unique patient exposures No deaths 133 adverse events reported in 81 patients 2001-2006, 27 adverse events related to FLECTOR ® Patch with most related to application site conditions (eg, skin rash) Alpharma Pharmaceuticals LLC; data on file.
Slide 61: Clinical Trials Overview
Clinical Trials Overview Study Indication Duration/ Regimen Number of Subjects Primary Endpoint Plasma diclofenac level 4 days/BID NA Comparative bioavailability VAS pain at Day 14 14 days/BID Minor Soft Tissue Injury Pivotal 1 (14-day study) VAS pain at Days 3 & 7 7 days/QD Minor Ankle Sprain Ankle
Slide 62: Pharmacokinetics and Comparative Bioavailability
Pharmacokinetics and Comparative Bioavailability Comparative bioavailability of FLECTOR ® Patch (diclofenac epolamine) and VOLTAREN ® (oral diclofenac sodium) in healthy volunteers Alpharma Pharmaceuticals LLC; data on file.
Slide 63: Mean Plasma Concentration Over Time
Mean Plasma Concentration Over Time FLECTOR ® Patch and VOLTAREN ® Oral Tablets Mean Plasma Concentration (ng/mL) Time (hours) FLECTOR ® Patch VOLTAREN ® Oral Tablets Alpharma Pharmaceuticals LLC; data on file. 0.01 0.1 1000 10000 400x Lower Systemic Blood Level
Slide 64: Comparison Between Plasma and Synovial Fluid
Comparison Between Plasma and Synovial Fluid with FLECTOR ® Patch Four hours after the application of FLECTOR ® Patch, a statistical difference between plasma and synovial fluid diclofenac concentrations was observed (p<0.05), the average amount of drug reaching the synovial fluid being 35.9% of tha
Slide 65: 7-Day Study
7-Day Study A controlled double-blind clinical study on the efficacy and safety of FLECTOR ® Patch versus placebo in minor ankle sprain Joussellin. J Traumatol Sport. 2003;20:1S5-1S9.
Slide 66: 7-Day Study: Decrease in Median Pain on First Day
7-Day Study: Decrease in Median Pain on Active Mobilization (%) Measured by Last VAS Value on First Day of Application * * * FLECTOR ® Patch placebo patch *Indicates Statistically Significant Difference ( P <0.05). Alpharma Pharmaceuticals LLC; data on file. -25 -20 -15 -10 -5 Hours after first appl
Slide 67: 7-Day Study: Decrease in Median Pain Days 0–3
7-Day Study: Decrease in Median Pain on Active Mobilization (%) Measured by Last VAS Value on Days 0–3 * * Decrease in Spontaneous Pain (%) Day Day Day Day * * * * 8 PM 8 AM Noon 8 PM 8 AM Noon 8 PM 8 AM Time Period *Statistically Significant Difference ( P <0.05). Alpharma Pharmaceuticals LLC; data
Slide 68: 7-Day Study: Decrease in Pain Days 3 & 7
7-Day Study: Decrease in Pain on Active Mobilization (%) Measured by Last VAS Value on Days 3 & 7 *Statistically Significant Difference ( P <0.05). Alpharma Pharmaceuticals LLC; data on file. * * Day 7 Consultation Day 3 Consultation FLECTOR ® Patch placebo patch -95 -90 -85 -80 -75 -70 -65 Decrease
Slide 69: 14-Day Study (Sport-2)
14-Day Study (Sport-2) A randomized, double-blind study of the analgesic efficacy and safety of the FLECTOR ® Patch in minor sports injury Alpharma Pharmaceuticals LLC; data on file.
Slide 70: 14-Day Study (Sport-2): Time to Pain Resolution
14-Day Study (Sport-2): Time to Pain Resolution Alpharma Pharmaceuticals LLC; data on file. P =0.009 FLECTOR ® Patch (median=8.8 days) placebo patch (median=12.4 days) Study Day Percent With Success
Slide 71: Pivotal (14-Day Study)
Pivotal 1 (14-Day Study) A randomized, double-blind, placebo-controlled study of the analgesic efficacy and safety of the diclofenac epolamine patch in minor soft tissue injury Alpharma Pharmaceuticals LLC; data on file.
Slide 72: 14-Day Study: Primary Efficacy
69 14-Day Study: Primary Efficacy *Statistically Significant Result Relative to Placebo Group (P<0.05). Alpharma Pharmaceuticals LLC; data on file. VAS Score as a Proportion of Baseline (Mean ? Standard Error) * 0.50 0.48 0.46 0.44 0.42 0.40 0.38 0.36 placebo patch FLECTOR(r) Patch
Slide 73: FLECTOR Patch: 14-Day Study Time to Injury Resolution
FLECTOR ® Patch: 14-Day Study Time to Injury Resolution FLECTOR ® Patch placebo patch Median Time to Pain Resolution Alpharma Pharmaceuticals LLC; data on file. [Beks P, et al. Manuscript in preparation]. P =0.007 5.5 7.5
Slide 74: 14-Day Studies: Time to Injury Resolution
14-Day Studies: Time to Injury Resolution Alpharma Pharmaceuticals LLC; data on file. Ekman EF, et al. Am J Orthop. 2002;31:445-451. ® P =0.007 Pivotal 1 (2004) Ekman (2002) 5.5 7.5 FLECTOR Patch placebo patch Celecoxib Ibuprofen Placebo
Slide 75: Safety Data From US Clinical Trials
Safety Data From US Clinical Trials FLECTOR(r) Patch (N=572) placebo patch (N=564) Application Site Conditions Pruritus Dermatitis Burning Other 64 (11%) 31 (5%) 9 (2%) 2 (<1%) 22 (4%) 70 (12%) 44 (8%) 3 (<1%) 8 (1%) 15 (3%) Gastrointestinal Disorders Nausea Dysgeusia Dyspepsia Other 49 (9%) 17 (3%)
Slide 76: Overall Conclusions
73 Overall Conclusions Efficacy The FLECTOR(r) Patch is efficacious in relieving acute pain associated with minor injuries such as sprains, strains, and contusions Pain relief with the FLECTOR(r) Patch occurred as early as 4 hours after the first application (7-day study) Time to pain resolution (4
Slide 77: FLECTOR Patch Launch
Scott Shively Sr. Vice President Sales & Marketing FLECTOR ® Patch Launch
Slide 78: FLECTOR Patch Commercial Launch Plan
FLECTOR® Patch Commercial Launch Plan Introduction to the Product Summary of Market Research Promotional Campaign Marketing Pre-Launch and Launch Plans Sales Force Strategy Managed Care Strategy
Slide 79: Critical Success Factors to Build Pain Franchise
Critical Success Factors to Build Pain Franchise Customer Understanding Proactive with Competition Creativity Executional Excellence Highly Strategic Approach People
Slide 80: Flector (diclofenac epolamine topical patch) 1.3%
Flector; (diclofenac epolamine topical patch) 1.3% @ ALPHARMA. Pharmaceuticals
Slide 81: FLECTOR Patch: Characteristics
FLECTOR ® Patch: Characteristics 10 cm X 14 cm Patch Felt backing (against clothing) Adhesive surface (against skin) Transparent release liner (removed prior to application)
Slide 82: FLECTOR Patch: Commercial Packaging
FLECTOR ® Patch: Commercial Packaging Single patch 5 patches in a pouch 6 pouches in a box
Slide 83: FLECTOR Patch Primary Market Research
FLECTOR ® Patch Primary Market Research Project Objective FLECTOR ® patch has been extensively tested in market research with over 530 physicians in addition to multiple marketing advisory boards Pain Product Profile Evaluation Obtain reactions to topical pain products FLECTOR® Patch Positioning Stu
Slide 84: Physicians Are Very Responsive to FLECTOR Patch
N=245 Very unfavorable Very favorable Overall Impression of FLECTOR(r) Patch Profile Physicians Are Very Responsive to FLECTOR(r) Patch 1 2 3 4 5 East 0 0.020408163 0.179591837 0.636734694 0.163265306
Slide 85: Market Research Summary of Key Findings
FLECTOR® Patch Market Research Summary of Key Findings FLECTOR® Patch product profile elicits extremely favorable reactions from physicians in all market research studies Physicians would allocate to FLECTOR® Patch a significant share of their acute, mild-to-moderate pain patients that would have be
Slide 86: Market Research Key Findings (continued)
FLECTOR® Patch Market Research Key Findings (continued) Several key potential advantages of the FLECTOR ® Patch were identified Safe/well tolerated – comparable to placebo Minimal systemic absorption Effective analgesia Analgesia directly at the painful site (due to the topical application) Some phy
Slide 87: Market Research Evaluation Verbatims
FLECTOR® Patch Market Research Evaluation Verbatims “ I like the idea that it is a non-steroidal in the form of a patch. Because there is minimal systemic absorption , you are bypassing a lot of side effects that would be caused otherwise.” RHEUMATOLOGIST “ It is a familiar drug, so it gives you som
Slide 88: The 1st and only topical NSAID Patch
The 1st and only topical NSAID Patch Introducing Draft concept tested in marketing research. Currently under review at DDMAC and may not be use for promotional purposes
Slide 89: Launching FLECTOR Patch With Channel Synergies
Launching FLECTOR ® Patch With Channel Synergies PR Sales Branded Medical Education Promotion LAUNCH MSL Round Tables Managed Markets
Slide 90: FLECTOR Patch Pre-Launch Activities
Aug 07’ Sep 07’ Oct 07’ Nov 07’ Dec 07’ Jan 08’ Positioning and Concept Development Sales Aid and Journal Ad Testing and Development Develop Pricing and Managed Care Strategy Flector.com Website Recruit Sales Force Sales Force Training Amer. College of Rheumatology Regional Ad Boards FLECTOR® Patch
Slide 91: Creating Momentum Prior to Launch
Creating Momentum Prior to Launch Journal Advertisements Total Hits = 500,000 Direct Mail – Alert Marketing PCP Reach = 77,000 NP/PA Reach = 99,000 Regional Advisory Boards Nationwide Attendees = 280+ New England Journal of Medicine American Medical News Internal Medicine News Family Practice News P
Slide 92: Sales Force Strategy: Call Plan
Sales Force Strategy FLECTOR® Patch Call Plan Decile 10 Alpharma Sales Force CSO Decile 1 Decile 5 Efficient Promotional Targeting
Slide 93: Efficient Sales Force Overlap and Coverage
Efficient Sales Force Overlap and Coverage of the FLECTOR ® Patch and KADIAN®/EMBEDA™ Markets High Potential KADIAN®/EMBEDA ™ Targets 42,420 High Potential FLECTOR® Patch Targets 47,944 42,364 5,580 48,000 Targets FLECTOR® Patch Targets KADIAN® Targets Overlapping Targets Efficient Targeting; 90% Ov
Slide 94: Building the Sales Force – Ramped Up to Launch
Building the Sales Force – Ramped Up to Launch Alpharma Sep 1, 2007 Jan 7, 2008 CSO # Reps Primary Detail Capacity Total For Launch Alpharma + = 319,000/yr 889,000/yr
Slide 95: Sales Force Expansion Complete
Sales Force Expansion Complete 224 new sales reps hired Average of 8 years sales experience Average of 5 years of pharma sales experience 46% have big pharma experience Companies recruited from include: Abbott, Astra-Zeneca, BMS, Cephalon, Eisai, Eli Lilly, Endo, Glaxo Smith Kline, J&J, King, Ligand
Slide 96: Managed Care (Payor) Response to FLECTOR Patch
Managed Care (Payor) Response to FLECTOR® Patch Most participants had a neutral to favorable reaction to the FLECTOR® Patch, focusing mostly on its route of administration and the minimal systemic absorption. Very unfavorable Unfavorable Neutral Very Favorable Favorable n=30 Overall, participants fe
Slide 97: Managed Care Strategy
Managed Care Strategy Achieve Commercial Managed Care Access for FLECTOR® Patch Tier two status to be achieved in significant number of targeted plans. Access to more than 110 million commercial lives Seek Medicare Coverage for FLECTOR® Patch Plans will act on new products within 180 days of commerc
Slide 98: Distribution Plan
Distribution Plan Wholesalers Launch deal and documentation sent out to wholesalers 11/15 Orders received 12/3-12/14 Began shipping 12/17 All wholesalers will have product by 12/19. Retailers Auto-ship program presented to all accounts All major national chains (e.g. Walgreens) and key regional chai
Slide 99: FLECTOR Patch Conclusion
FLECTOR® Patch…Conclusion Marketing Research has indicated very positive acceptance by physicians Sales Force is recruited and in training Pre-marketing plan executed, and awareness is building Initial Managed Care meetings underway – positive early acceptance Promotional materials under review at D
Slide 100: Grow KADIAN Business
Grow KADIAN Business Crisp Messaging & Targeted Tools Broader Target Audience With 400 Reps More Diverse Target Audience Second Position Detail IC Plan Aligned To Support Both KADIAN® as well as FLECTOR® Patch
Slide 101: Building the Pain Franchise one Specialty-Buster at a Time
Building the Pain Franchise one “Specialty-Buster” at a time EMBEDA ™
Slide 102: EMBEDA Overview
EMBEDA ™ Overview Joseph W. Stauffer, DO Chief Medical Officer Senior Vice President Clinical Research & Medical Affairs Alpharma Pharmaceuticals, LLC Adjunct Assistant Professor Johns Hopkins University Hospital Department of Anesthesiology & Critical Care Medicine Division of Pain Medicine
Slide 103: What we'll talk about
What we’ll talk about… EMBEDA ™ Technology Pivotal Efficacy Data Pivotal Safety Data to Date New Abuse Deterrent Data Summary
Slide 104: How Does the EMBEDA Abuse-deterrent Technology Work?
2. If EMBEDA ™ is crushed, chewed or extracted: A. the naltrexone (opioid antagonist) releases and mixes with morphine B. the morphine-naltrexone mixture is intended to prevent euphoria from morphine by competing for the same opioid receptor in the brain…thus deterring abuse of the product 1. If tak
Slide 105: Pivotal Efficacy Study
Pivotal Efficacy Study Objective Evaluate efficacy and safety of EMBEDA ™ vs. placebo for chronic moderate to severe pain Study Design Conducted Under Special Protocol Assessment (SPA) Open-label titration phase Double-blind maintenance phase
Slide 106: Assessments
Assessments Primary Efficacy Measure Change from baseline to the end of maintenance phase Brief Pain Inventory (BPI) score of average pain Secondary Endpoints BPI Average Pain from Daily Diary WOMAC Pain Subscale WOMAC Composite Score Medical Outcomes Study (MOS) sleep scale Beck Depression Inventor
Slide 107: Efficacy – Primary Endpoint
Efficacy – Primary Endpoint Mean Change From in-Clinic Baseline BPI Average Pain Score Mean Change From Baseline BPI Average Pain Score *PI scale: 0 = no pain, 10 = pain as bad as you can imagine p=0.04 ™ 2.9 3.1 3.2 3.3 3.4 3.5 3.6 Randomization Baseline 12 Weeks EMBEDA Placebo
Slide 108: BPI Average Pain Score Daily Diary
Taper period BPI Average Pain Score Daily Diary p=0.001 p=0.005 p=0.001 p=0.001 p=0.001 p=0.007 *PI scale: 0 = no pain, 10 = pain as bad as you can imagine ™ 0.5 1.5 2.5 3.5 Week 0 Week 6 Week 12 Placebo EMBEDA
Slide 109: WOMAC Pain Subscale Score
Taper period WOMAC Pain Subscale Score p=0.05 p=0.02 p=0.02 p=0.003 ™ Week 0 Week 6 Week 12 Placebo EMBEDA
Slide 110: WOMAC Composite Score
Taper period WOMAC Composite Score p=0.04 p=0.03 p=0.04 p=0.03 p=0.02 ™ Week 0 Week 6 Week 12 Placebo EMBEDA
Slide 111: Secondary Endpoints
Secondary Endpoints ITT Population Endpoint, Mean (+-SD) Change from First Visit to Week 12 Change from First Visit to Week 12 Change from First Visit to Week 12 Endpoint, Mean (+-SD) Placebo N=173 EMBEDA N=170 p- value BPI diary average pain score 0.8 (1.94) 0.3 (1.91) 0.0048 WOMAC Pain Subscale 5.
Slide 112: At Three Months, No Statistical Difference
Study 301 Safety Population Deaths, n (%) 0.8185 9 (5.3) 11 (6.4) Severe TEAEs , n (%) 0.8324 12 (7.0) 11 (6.4) TEAEs leading to discontinuation, n (%) 0.1932 56 (32.7) 45 (26.0) Drug-related TEAE,* n (%) 0.3909 91 (51.2) 84 (48.6) Any treatment-emergent adverse event (TEAE) , n (%) p- value EMBEDA
Slide 113: Pivotal Safety Study
Pivotal Safety Study 302 Objective Evaluate long-term safety of EMBEDA ™ over 12 months in patients with chronic moderate to severe pain Study Design Phase 3, multi-center, open-label, long-term study Dose titration Initial dose: Opioid-naïve subjects 20 mg BID Subjects who took opioids previously d
Slide 114: Patient Global Assessment of EMBEDA
Patient Global Assessment of EMBEDA(tm) ITT Population <80mg 80-120mg >120mg Overall Good+Very good+Excellent 95 90 88.9 93.1 Excellent 37.2 32.5 25.9 34.6 Very good 39.7 40 40.7 39.9 Good 18.2 17.5 22.2 18.6 Fair 5 10 7.4 6.4 Poor 0 0 3.7 0.5 6 Months % of Patients
Slide 115: Naltrexone Levels Measured
Naltrexone Levels Measured Highly sensitive assay No appreciable naltrexone detected Similar outcome to Phase II No correlation between naltrexone level and clinical effect
Slide 116: Abuse Deterrent Study Design
Phase 1 Study 205 Objective Determine relative pharmacodynamic effects and safety of (1) crushed and whole ALO-01 compared to Morphine Sulfate IR and placebo and of (2) crushed ALO-01 to whole ALO-01 Study Design Screening/Qualifying period (up to 56 days) 3-night inpatient double-blind qualifying s
Slide 117: Study Pharmacodynamic
Study 205 Pharmacodynamic Cole/ARCI Stimulation Euphoria Peak Plasma Morphine Concentration, t=1.5 h 0.755 Whole ALO-01 – Placebo @ 1.5 h 0.089 Crushed ALO-01 – Placebo @ 1.5 h <.001 Morphine IR – ALO01 whole @ 1.5 h <.001 Morphine IR – ALO-01 crushed @ 1.5 h <.001 Morphine IR – Placebo @ 1.5 h Trip
Slide 118: Study Pharmacodynamic
Study 205 Pharmacodynamic <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 Morphine IR - ALO-01 whole <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 Morphine IR - ALO-01 crushed <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 Morphine IR – Placebo Treatment effect 1.5 h <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.00
Slide 119: Summary
Summary EMBEDA ™ …if taken as directed significantly decreases chronic pain Is safe and well tolerated with adverse events consistent with morphine and other Long-acting opioids EMBEDA ™ …if tampered with Demonstrates Significant Abuse-Deterrent Features
Slide 120: Wrap Up
Wrap Up Dean Mitchell President and CEO
Slide 121: Strategic Direction
Strategic Direction Create a high value specialty pharmaceutical business Three strong businesses with varying opportunities to achieve further growth and profitability organically and through business development activities Innovation funded from cash flows and financing Build capabilities to drive
Slide 122: As We Enter 2008
As We Enter 2008 Significant market opportunities Targeted investments to drive sustainable growth Rigorous operating cost discipline and cash generation Strong financial position Continuous focus on capital structure and portfolio to maximize shareholder value Positioned for Growth and Value Creati
Slide 123: 2008 Targeted Milestones
2008 Targeted Milestones Pharmaceuticals API Animal Health FLECTOR(r) Patch launch KADIAN(r) revenue growth EMBEDA(tm) NDA filing Leverage abuse deterrent technology to other molecules Continue vancomycin growth Commercialize injectable production Commercialize Chinese vancomycin capacity Introduce
Slide 124: To Sum Up
Strategic transformation… entering second year of execution Increased confidence in strategic potential and our ability to execute based on strong 2007 performance To Sum Up… Investing to Create Significant Shareholder Value
Slide 125: Questions and Answers
Questions and Answers December 18, 2007 Investor Meeting